🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What will it take to revolutionize #cancer care? We're pioneering a new path that combines CAR-T cell therapy and our own T-SIGn® therapeutics. Learn more: #immunooncology

Akamis Bio is featured in BioIndustry Association (BIA)’s #biotech #financing report for Q1 2023. Check it out 👇

📍 2013: The academic journal Science names cancer immunotherapy “Breakthrough of the Year” in the face of remarkable recoveries and improved patient survival in cancer patients! Learn more, and explore our entire timeline of discovery: bit.ly/3XJspfe #Immunotherapy

May is National Cancer Research Month. A month to show gratitude to the scientists working every day to better the lives of people diagnosed with #cancer. On behalf of the entire Akamis Bio team, thank you, cancer researchers. We are proud to work alongside you. #NCRM23

Are you ready for ASCO? The Akamis team is! Join us June 3 at 8am CT, as we present the impact of intravenous vs intratumoral delivery during the Phase 1 FORTITUDE study. #ASCO2023 #ImmunoOncology

Join us in celebrating Cancer Immunotherapy Awareness Month to recognize the revolutionary research that has provided our field with #immunotherapy. In this very Akamis Bio lab we are preparing to help people with #cancer by harnessing our T-SIGn® platform bit.ly/3LVuIY7

With more than 200 #patients treated across our clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of clinical activity. Learn more about our growing our #pipeline: bit.ly/3pPRxoR

We are pleased to announce new leadership appointments at Akamis Bio! Learn more about our work to transform the delivery and efficacy of immuno-oncology treatments for solid tumors: bit.ly/46Czint

Akamis Bio aims to transform the treatment of advanced #solidtumors, with I.V. administered, tumor-specific therapeutics that can generate a potent immune response and avoid systemic toxicity. Learn more about our T-SIGn® therapeutics platform: bit.ly/3MSj4zp

Akamis Bio’s T-SIGn therapeutics are designed to modulate the #tumor microenvironment, enabling the local production of potent immuno-therapeutics that drive robust anti-tumor immune responses to recognize, attack and clear solid tumors. Learn more: bit.ly/3Kwi5mv

See how our T-SIGn® platform is working to advance cell therapies for solid tumors, with novel vectors that can help express target antigens to enhance the activation, survival, and efficacy of cell therapies in the #solidtumor setting bit.ly/3KBtscH

Check out this recent article from Cell&Gene featuring our CEO, Howard Davis, Ph.D., who discusses Akamis Bio’s portfolio of T-SIGn #therapeutics, our NG-350A clinical trial, and how T-SIGn is broadening the impact of cell therapy in #solidtumors: bit.ly/45QO3T2

Akamis Bio is working to enhance #immunotherapy by addressing the safety and efficacy challenges of treating #solidtumors. Learn how our T-SIGn® therapeutics aim to drive a powerful tumor-specific immune response while avoiding systemic toxicity: bit.ly/3pPRxoR

Learn more about Akamis Bio’s lead program, NG-350A, a Phase 1 immuno-stimulatory #genetherapy that aims to safely drive intra-tumoral expression of a potent CD-40 agonist to treat solid #cancer tumors: bit.ly/3pPRxoR

Akamis Bio will share data at #ASTRO2023 from the Phase 1 CEDAR study which showed improved responses in patients with locally advanced rectal #cancer treated with radiotherapy in combination with our adenovirus vector #technology, over radiation alone bit.ly/3Q0Axqr

Akamis Bio CEO Howard Davis, Ph.D., was featured on The Bio Report podcast with Daniel S. Levine where they discussed the potential of T-SIGn therapeutics to treat solid tumors both as monotherapies and in combination with a range of cell therapies. Listen now: bit.ly/3M55NSO

Samantha Bailey-Bucktrout will be speaking at the #PEGSEurope Conference to discuss how we use our T-SIGn platform to express novel antibody combinations, recent advances in our lead program NG-350A, and new transgene combinations to boost CAR-T activity: bit.ly/3Szx1F8

Tune in to the Careers in Discovery #podcast with Tom Froggatt to hear Samantha Bailey-Bucktrout discuss her #career and current role leading research at Akamis Bio, and the potential of systemically delivered T-SIGn therapeutics to treat solid tumors: bit.ly/3uzQlYV

Thrilled to announce the completion of Akamis Bio’s Series A Prime financing and new strategic partnership which provide funding to support the advancement of our lead oncology candidate, NG-350A, into a clinical proof-of-concept study in patients with locally advanced rectal

We are pleased to announce enrollment of the first patient in our Phase 1b FORTRESS trial of NG-350A for the treatment of locally advanced rectal cancer (LARC), a key milestone toward advancing a novel immunotherapy and potentially transforming standard of care. Learn more: